Centers for Disease Control and Prevention Centers for Disease Control and Prevention CDC Home Search CDC CDC Health Topics A-Z site search
National Office of Public Health Genomics
Centers for Disease Control and Prevention
Office of Genomics and Disease Prevention
Site Search
 

HuGENet Review
Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review
Melissa A. Austin  1, Carolyn M. Hutter1, Ron L. Zimmern2 and Steve E. Humphries 3
back to review

 REFERENCES
  1. Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand 1938;89:75–84.
  2. Khachadurian AK. The inheritance of essential familial hypercholesterolemia. Am J Med 1964;37:402–7.
  3. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins—an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:215–25.
  4. Ott J, Schrott HG, Goldstein JL, et al. Linkage studies in a large kindred with familial hypercholesterolemia. Am J Hum Genet 1974;26:598–603.
  5. Elston RC, Namboodiri KK, Go RC, et al. Probable linkage between essential familial hypercholesterolemia and third complement component (C3). Cytogenet Cell Genet 1976;16:294–7.
  6. Berg K, Heiberg A. Linkage between familial hypercholesterolemia with xanthomatosis and the C3 polymorphism confirmed. Cytogenet Cell Genet 1978;22:621–3.
  7. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34–47.
  8. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171–6.
  9. Goldstein JL, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill Companies, Inc, 1989:1215–50.
  10. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007–12.
  11. Yamamoto A, Kamiya T, Yamamura T, et al. Clinical features of familial hypercholesterolemia. Arteriosclerosis 1989;9 (1 suppl):I66–74.
  12. Williams RR, Hasstedt SJ, Wilson DE, et al. Evidence that men with familial hypercholesterolemia can avoid early coronary death. An analysis of 77 gene carriers in four Utah pedigrees. JAMA 1986;255:219–24.
  13. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;303:893–6.
  14. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999;142:105–12.
  15. World Health Organization. Familial hypercholesterolemia—report of a second WHO Consultation. Geneva, Switzerland: World Health Organization, 1999. (WHO publication no. WHO/HGN/FH/CONS/99.2).
  16. Kwiterovich PO Jr, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest 1974;53:1237–49.
  17. Leonard JV, Wolfe OH, Lloyd J, et al. Diagnosing familial hypercholesterolaemia in childhood. Br Med J 1977;2:455–6.
  18. Marks D, Thorogood M, Neil HA, et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1–14.
  19. Vuorio AF, Turtola H, Piilahti KM, et al. Familial hypercholesterolemia in the Finnish north Karelia. A molecular, clinical, and genealogical study. Arterioscler Thromb Vasc Biol 1997;17:3127–38.
  20. Goldstein JL, Schrott HJ, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544–68.
  21. Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet 1972;1:393–9.
  22. Slack J. Inheritance of familial hypercholesterolemia. Atheroscler Rev 1979; 5:35–66.
  23. Mabuchi H, Haba T, Ueda K, et al. Serum lipids and coronary heart disease in heterozygousfamilial hypercholesterolemia in the Hokuriku District of Japan. Atherosclerosis 1977;28:417–23.
  24. Heiberg A, Berg K. The inheritance of hyperlipoproteinaemia with xanthomatosis. A study of 132 kindreds. Clin Genet 1976;9:203–33.
  25. Andersen GE, Lous P, Friis-Hansen B. Screening for hyperlipoproteinemia in 10,000 Danish newborns. Follow-up studies in 522 children with elevated cord serum VLDL-LDL-cholesterol. Acta Paediatr Scand 1979;68:541–5.
  26. Kalina A, Csaszar A, Czeizel AE, et al. Frequency of the R3500Q mutation of the apolipoprotein B-100 gene in a sample screened clinically for familial hypercholesterolemia in Hungary. Atherosclerosis 2001;154:247–51.
  27. Neil HA, Hammond T, Huxley R, et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000;321:148.
  28. Moorjani S, Roy M, Gagne C, et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 1989;9:211–16.
  29. Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J 1980;281:633–6.
  30. Seftel HC, Baker SG, Jenkins T, et al. Prevalence of familial hypercholesterolemia in Johannesburg Jews. Am J Med Genet 1989;34:545–7.
  31. Rubinsztein DC, van der Westhuyzen DR, Coetzee GA. Monogenic primary hypercholesterolaemia in South Africa. S Afr Med J 1994;84:339–44.
  32. Slimane MN, Pousse H, Maatoug F, et al. Phenotypic expression of familial hypercholesterolaemia in central and southern Tunisia. Atherosclerosis 1993;104:153–8.
  33. Gudnason V, Sigurdsson G, Nissen H, et al. Common founder mutation in the LDL receptor gene causing familial hypercholesterolaemia in the Icelandic population. Hum Mutat 1997; 10:36–44.
  34. Vuorio AF, Aalto-Setala K, Koivisto UM, et al. Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group. Ann Med 2001;33:410–21.
  35. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Sly WS, Childs B, et al, eds. The metabolic and molecular bases of inherited disease. New York, NY: McGraw-Hill Companies, Inc, 2001:2863–914.
  36. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974;249:5153–62.
  37. Brown MS, Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science 1974;185:61–3.
  38. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984;39:27–38.
  39. Lindgren V, Luskey KL, Russell DW, et al. Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. Proc Natl Acad Sci U S A 1985;82:8567–71.
  40. Rudenko G, Henry L, Henderson K, et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science 2002;298:2353–8.
  41. Innerarity TL. Structural biology. LDL receptor’s beta- propeller displaces LDL. Science 2002;298:2337–9.
  42. Soria LF, Ludwig EH, Clarke HR, et al. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A 1989;86:587–91.
  43. Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A 1987;84:6919–23.
  44. Knott TJ, Rall SC Jr, Innerarity TL, et al. Human apolipoprotein B: structure of carboxyl-terminal domains, sites of gene expression, and chromosomal localization. Science 1985;230:37–43.
  45. Law SW, Lackner KJ, Hospattankar AV, et al. Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assignment of the gene to chromosome 2. Proc Natl Acad Sci U S A 1985;82:8340–4.
  46. Law SW, Lee N, Monge JC, et al. Human ApoB-100 gene resides in the p23––pter region of chromosome 2. Biochem Biophys Res Commun 1985;131:1003–12.
  47. Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990;31:1337–49.
  48. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001;292:1394–8.
  49. Eden ER, Naoumova RP, Burden JJ, et al. Use of homozygosity mapping to identify a region on chromosome 1 bearing a defective gene that causes autosomal recessive homozygous hypercholesterolemia in two unrelated families. Am J Hum Genet 2001;68:653–60.
  50. Lee MH, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001;27:79–83.
  51. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000;290:1771–5.
  52. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr Metab 1973;15:132–40.
  53. Zuliani G, Arca M, Signore A, et al. Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol1999;19:802–9.
  54. Arca M, Zuliani G, Wilund K, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002;359:841–7.
  55. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2003;23:1963–70.
  56. Fellin R, Zuliani G, Arca M, et al. Clinical and biochemical characterisation of patients with autosomal recessive hypercholesterolemia (ARH). Nutr Metab Cardiovasc Dis 2003;13:278–86.
  57. Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974;53:1033–43.
  58. Goldstein JL, Brown MS. Molecular medicine. The cholesterol quartet. Science 2001;292:1310–12.
  59. Lu K, Lee MH, Hazard S, et al. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001;69:278–90.
  60. Varret M, Rabes JP, Saint-Jore B, et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet 1999;64:1378–87.
  61. Hunt SC, Hopkins PN, Bulka K, et al. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol 2000;20:1089–93.
  62. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154–6.
  63. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992;1:445–66.
  64. Day IN, Whittall RA, O’Dell SD, et al. Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolemia. Hum Mutat 1997;10:116–27.
  65. Heath KE, Gahan M, Whittall RA, et al. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis 2001;154:243–6.
  66. Villeger L, Abifadel M, Allard D, et al. The UMD-LDLR database: additions to the software and 490 new entries to the database. Hum Mutat 2002;20:81–7.
  67. Hobbs HH, Russell DW, Brown MS, et al. The LDL receptor locus and familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990;24:133–70.
  68. Gudnason V, Day IN, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler Thromb 1994;14:1717–22.
  69. Hobbs HH, Brown MS, Russell DW, et al. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987;317:734–7.
  70. Neff D, Ruschitzka F, Hersberger M, et al. Detection of a novel exon 4 low-density lipoprotein receptor gene deletion in a Swiss family with severe familial hypercholesterolemia. Clin Chem Lab Med 2003;41:266–71.
  71. Heath KE, Day IN, Humphries SE. Universal primer quantitative fluorescent multiplex (UPQFM) PCR: a method to detect major and minor rearrangements of the low density lipoprotein receptor gene. J Med Genet 2000;37:272–80.
  72. Fisher E, Scharnagl H, Hoffmann MM, et al. Mutations in the apolipoprotein (apo) B-100 receptor-binding region: detection of apo B-100 (Arg3500-->Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405-->Gln) diminishes receptor-mediated uptake of LDL. Clin Chem 1999;45:1026–38.
  73. Pullinger CR, Hennessy LK, Chatterton JE, et al. Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. J Clin Invest 1995;95:1225–34.
  74. Bednarska-Makaruk M, Bisko M, Pulawska MF, et al. Familial defective apolipoprotein B-100 in a group of hypercholesterolaemic patients in Poland. Identification of a new mutation Thr3492Ile in the apolipoprotein B gene. Eur J Hum Genet 2001;9:836–42.
  75. Nissen H, Hansen PS, Faergeman O, et al. Mutation screening of the codon 3500 region of the apolipoprotein B gene by denaturing gradient-gel electrophoresis. Clin Chem 1995;41:419–23.
  76. Ludwig EH, McCarthy BJ. Haplotype analysis of the human apolipoprotein B mutation associated with familial defective apolipoprotein B100. Am J Hum Genet 1990;47:712–20.
  77. Rabes JP, Varret M, Devillers M, et al. R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:E76–82.
  78. Tybjaerg-Hansen A, Steffensen R, Meinertz H, et al. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 1998;338:1577–84.
  79. Ludwig EH, Hopkins PN, Allen A, et al. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J Lipid Res 1997;38:1361–73.
  80. Gaffney D, Reid JM, Cameron IM, et al. Independent mutations at codon 3500 of the apolipoprotein B gene are associated with hyperlipidemia. Arterioscler Thromb Vasc Biol 1995;15:1025–9.
  81. Boren J, Ekstrom U, Agren B, et al. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem 2001;276:9214–18.
  82. Bersot TP, Russell SJ, Thatcher SR, et al. A unique haplotype of the apolipoprotein B-100 allele associated with familial defective apolipoprotein B-100 in a Chinese man discovered during a study of the prevalence of this disorder. J Lipid Res 1993;34:1149–54.
  83. Hansen PS, Norgaard-Petersen B, Meinertz H, et al. Incidence of the apolipoprotein B-3500 mutation in Denmark. Clin Chim Acta 1994;230:101–4.
  84. Miserez AR, Laager R, Chiodetti N, et al. High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 1994;35:574–83.
  85. Miserez AR, Muller PY. Familial defective apolipoprotein B-100: a mutation emerged in the mesolithic ancestors of Celtic peoples? Atherosclerosis 2000;148:433–6.
  86. Kotze MJ, Loubser O, Thiart R, et al. CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet 1997;51:394–8.
  87. Lehrman MA, Schneider WJ, Brown MS, et al. The Lebanese allele at the LDL receptor locus: nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum. J Biol Chem 1987;262:401–10.
  88. Slimane MN, Lestavel S, Sun X, et al. Fh-Souassi: a founder frameshift mutation in exon 10 of the LDL-receptor gene, associated with a mild phenotype in Tunisian families. Atherosclerosis 2001;154:557–65.
  89. Miltiadous G, Elisaf M, Bairaktari H, et al. Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece. Hum Mutat 2001;17:432–3.
  90. Khoo KL, van Acker P, Defesche JC, et al. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. Clin Genet 2000;58:98–105.
  91. Reshef A, Nissen H, Triger L, et al. Molecular genetics of familial hypercholesterolemia in Israel. Hum Genet 1996;98:581–6.
  92. Sun XM, Patel DD, Knight BL, et al. Comparison of the genetic defect with LDL-receptor activity in cultured cells from patients with a clinical diagnosis of heterozygous familial hypercholesterolemia. The Familial Hypercholesterolaemia Regression Study Group. Arterioscler Thromb Vasc Biol 1997;17:3092–101.
  93. Maruyama T, Miyake Y, Tajima S, et al. Common mutations in the low-density-lipoprotein-receptor gene causing familial hypercholesterolemia in the Japanese population. Arterioscler Thromb Vasc Biol 1995;15:1713–18.
  94. Jensen HK, Jensen LG, Meinertz H, et al. Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia. Atherosclerosis 1999;146:337–44.
  95. Alberto FL, Figueiredo MS, Zago MA, et al. The Lebanese mutation as an important cause of familial hypercholesterolemia in Brazil. Braz J Med Biol Res 1999;32:739–45.
  96. Pimstone SN, Sun XM, du Souich C, et al. Phenotypic variation in heterozygous familial hypercholesterolemia: a comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada. Arterioscler Thromb Vasc Biol 1998;18:309–15.
  97. Peeters AV, Van Gaal LF, du Plessis L, et al. Mutational and genetic origin of LDL receptor gene mutations detected in both Belgian and Dutch familial hypercholesterolemics. Hum Genet 1997;100:266–70.
  98. Salazar LA, Hirata MH, Cavalli SA, et al. Molecular basis of familial hypercholesterolemia in Brazil: identification of seven novel LDLR gene mutations. Hum Mutat 2002;19:462–3.
  99. Wang J, Huff E, Janecka L, et al. Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent. (Mutation in brief). Hum Mutat 2001;18:359.
  100. Thiart R, Scholtz CL, Vergotine J, et al. Predominance of a 6 bp deletion in exon 2 of the LDL receptor gene in Africans with familial hypercholesterolaemia. J Med Genet 2000;37:514–19.
  101. Mak YT, Pang CP, Tomlinson B, et al. Mutations in the low-density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients. Arterioscler Thromb Vasc Biol 1998;18:1600–5.
  102. Yu W, Nohara A, Higashikata T, et al. Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis 2002;165:335–42.
  103. Kuhrova V, Francova H, Zapletalova P, et al. Spectrum of low density lipoprotein receptor mutations in Czech hypercholesterolemic patients. (Mutation in brief). Hum Mutat 2002;19:80.
  104. Nauck MS, Koster W, Dorfer K, et al. Identification of recurrent and novel mutations in the LDL receptor gene in German patients with familial hypercholesterolemia. Hum Mutat 2001;18:165–6.
  105. Liguori R, Bianco AM, Argiriou A, et al. LDL receptor cDNA sequence analysis in familial hypercholesterolemia patients: 5 novel mutations with high prevalence in families originating from southern Italy. (Mutation in brief). Hum Mutat 2001;17:433.
  106. Leren TP, Tonstad S, Gundersen KE, et al. Molecular genetics of familial hypercholesterolaemia in Norway. J Intern Med 1997;241:185–94.
  107. Garcia-Garcia AB, Real JT, Puig O, et al. Molecular genetics of familial hypercholesterolemia in Spain: ten novel LDLR mutations and population analysis. Hum Mutat 2001;18:458–9.
  108. Lind S, Rystedt E, Eriksson M, et al. Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene. Atherosclerosis 2002;163:399–407.
  109. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, et al. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet 2001;109:602–15.
  110. Day IN, Haddad L, O’Dell SD, et al. Identification of a common low density lipoprotein receptor mutation (R329X) in the south of England: complete linkage disequilibrium with an allele of microsatellite D19S394. J Med Genet 1997;34:111–16.
  111. Cotton RG, Scriver CR. Proof of "disease causing" mutation. Hum Mutat 1998;12:1–3.
  112. Loubser O, Marais AD, Kotze MJ, et al. Founder mutations in the LDL receptor gene contribute significantly to the familial hypercholesterolemia phenotype in the indigenous South African population of mixed ancestry. Clin Genet 1999;55:340–5.
  113. Simard J, Moorjani S, Vohl MC, et al. Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Hum Mol Genet 1994;3:1689–91.
  114. Leitersdorf E, Tobin EJ, Davignon J, et al. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest 1990;85:1014–23.
  115. Myant NB, Forbes SA, Day IN, et al. Estimation of the age of the ancestral arginine3500–>glutamine mutation in human apoB-100. Genomics 1997;45:78–87.
  116. Wilson J, Jungner YG. Principles and practice of mass screening for disease. Geneva, Switzerland: World Health Organization, 1968. (World Health Orgnaization public health paper no. 34).
  117. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57.
  118. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.
  119. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–9.
  120. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7.
  121. Bhatnagar D, Morgan J, Siddiq S, et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000;321:1497–500.
  122. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001;357:165–8.
  123. Goldman L, Goldman PA, Williams LW, et al. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993;72:75D–9D.
  124. World Health Organization. Familial hypercholesterolemia—report of a WHO Consultation. Paris, France: World Health Organization, 1997.
  125. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002;324:1303–8.
  126. Marang-van de Mheen PJ, ten Asbroek AH, Bonneux L, et al. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in the Netherlands. Eur Heart J 2002;23:1922–30.
  127. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol 2003;23:335–8.
  128. Mehta DK, ed. British national formulary, no. 39. London, United Kingdom: The Pharmaceutical Press, 2000.
  129. Marang-van de Mheen PJ, van Maarle MC, Stouthard ME. Getting insurance after genetic screening on familial hypercholesterolaemia; the need to educate both insurers and the public to increase adherence to national guidelines in the Netherlands. J Epidemiol Community Health 2002;56:145–7.
  130. Umans-Eckenhausen MA, Oort FJ, Ferenschild KC, et al. Parental attitude towards genetic testing for familial hypercholesterolaemia in children. J Med Genet 2002;39:e49.
  131. Neil HA, Hammond T, Mant D, et al. Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ 2004;328:500–1.
  132. Humphries SE, Galton D, Nicholls P. Genetic testing for familial hypercholesterolaemia: practical and ethical issues. QJM 1997;90:169–81.
  133. Graham CA, McClean E, Ward AJ, et al. Mutation screening and genotype:phenotype correlation in familial hypercholesterolaemia. Atherosclerosis 1999;147:309–16.
  134. Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000;4:1–123.
  135. Steyn K, Goldberg YP, Kotze MJ, et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet 1996;98:479–84.
  136. Hansen PS, Meinertz H, Jensen HK, et al. Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with familial defective apolipoprotein B-100. Arterioscler Thromb 1994;14:207–13.
Page last reviewed: April 26, 2004 (archived document)
Page last updated: November 2, 2007
Content Source: CDC's Office of Public Health Genomics